Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paula Ferreira Montenegro has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Michel Kahi

    Affiliation Université Côte d’Azur, Inserm U1065, C3M, Nice, France

    2 shared publications
  • Abigail Mazzu

    Université Côte d’Azur, Institut National de la Santé et de la Recherche Médicale, Nice, France

    1 shared publication
  • Elisabeth Taffin-De-Givenchy

    Marine Natural Products Team, Institut de Chimie de Nice, Université Côte d’Azur, CNRS UMR 7272, 06108 Nice, France

    1 shared publication
  • Fabien Fontaine-Vive

    Affiliation Université Côte d’Azur, CNRS UMR 7272, Institut de Chimie de Nice, Nice, France

    1 shared publication
  • Fatouma Mohamed Abdoul-Latif

    Medicinal Research Institute, Center for Research and Study of Djibouti, BP 486, Djibouti, Djibouti, Djibouti; Medicinal Research Institute, Centre d'Étude et de Recherche de Djibouti, Djibouti, Djibouti, Djibouti

    1 shared publication
  • Frederic Bost

    Affiliation Université Côte d’Azur, Inserm U1065, C3M, Nice, France

    1 shared publication

Latest Publications

  • Open Access

    Development of a reliable, sensitive, and convenient assay for the discovery of new eIF5A hypusination inhibitors

    by Oumayma Benaceur, Paula Ferreira Montenegro, Michel Kahi, Fabien Fontaine-Vive, Nathalie M. Mazure, Mohamed Mehiri, Frederic Bost, Pascal Peraldi

    EIF5A is a translation factor dysregulated in several pathologies such as cancer and diabetes. eIF5A activity depends upon its hypusination, a unique post-translational modification catalyzed by two enzymes: DHPS and DOHH. Only a few molecules able to inhibit hypusination have been described, and none are used for the treatment of patients. The scarcity of new inhibitors is probably due to the challenge of measuring DHPS and DOHH activities. Here, we describe the Hyp’Assay, a convenient cell-free assay to monitor eIF5A hypusination. Hypusination is performed in 96-well plates using recombinant human eIF5A, DHPS, and DOHH and is revealed by an antibody against hypusinated eIF5A. Pharmacological values obtained with the Hyp’Assay, such as the EC50 of DHPS for spermidine or the IC50 of GC7 for DHPS, were similar to published data, supporting the reliability of the Hyp’Assay. As a proof of concept, we synthesized four new GC7 analogs and showed, using the Hyp’Assay, that these derivatives inhibit hypusination. In summary, we present the Hyp’Assay; a reliable and sensitive assay for new hypusination inhibitors. This assay could be of interest to researchers wanting an easier way to study hypusination, and also a valuable tool for large-scale screening of chemical libraries for new hypusination inhibitors.


  • Open Access

    The marine-derived HIF-1α inhibitor, Yardenone 2, reduces prostate cancer cell proliferation by targeting HIF-1 target genes

    by Siyong Peng, Yingbo Guo, Marie Irondelle, Abigail Mazzu, Michel Kahi, Paula Ferreira Montenegro, Frédéric Bost, Nathalie M. Mazure

    Background: Prostate cancer (PCa) ranks as the second most prevalent cancer in men, with advanced stages posing significant treatment challenges. Given its solid tumor nature, PCa is highly susceptible to hypoxia, a condition associated with resistance to radiation and chemotherapy, metastasis, and unfavorable patient outcomes. Hypoxia-inducible factors (HIFs) play a pivotal role in cancer cell adaptation to hypoxic environments, contributing to treatment resistance. Consequently, inhibitors targeting HIFs hold promise for cancer therapy. Methods: In this study, we aimed to characterize novel HIF-1α inhibitors including Sodwanones A (1), B (2), C (3), G (4) and Yardenone 2 (5) isolated from marine sponges belonging to the Axinella genus. Our investigation evaluated the impact of these compounds on various aspects of HIF-1α regulation, including stabilization, nuclear localization, expression of HIF-1 target genes (while sparing HIF-2 target genes), cellular metabolism, as well as cell proliferation and viability in prostate cells under hypoxic conditions. Results: Our findings revealed that among the compounds tested, Yardenone 2 exhibited notable effects in hypoxia: it destabilized HIF-1α at the protein level, decreased its nuclear localization, selectively altered the expression of HIF-1 target genes, and restrained cell proliferation in aggressive PC3 prostate cancer cells as well as in an MSK-PCa3 patient-derived organoid line. Moreover, it affected the morphology of these organoid. Yardenone 2 was also compared to Docetaxel, a specific microtubule inhibitor and a drug used in the treatment of prostate cancer. The comparison between the two compounds revealed notable differences, such as a lack of specificity to hypoxic cells of Docetaxel. Conclusion: These results mark the first demonstration that Yardenone 2 functions as a cytostatic-like inhibitor impacting microtubules, specifically targeting hypoxic cancer cells. This discovery suggests a promising avenue for novel therapeutic interventions in prostate cancer.


  • Open Access

    Marine Bromotyrosine Derivatives in Spotlight: Bringing Discoveries and Biological Significance

    by Paula Ferreira Montenegro, Giang Nam Pham, Fatouma Mohamed Abdoul-Latif, Elisabeth Taffin-De-Givenchy, Mohamed Mehiri

    The Verongida order comprises several sponge families, such as Aplysinellidae, Aplysinidae, Ianthellidae, and Pseudoceratinidae, reported for producing bromotyrosine-derived compounds. First identified in 1913, bromotyrosine derivatives have since captivated interest notably for their antitumor and antimicrobial properties. To date, over 360 bromotyrosine derivatives have been reported. Our review focuses specifically on bromotyrosine derivatives newly reported from 2004 to 2023, by summarizing current knowledge about their chemical diversity and their biological activities.